NTRO Announces Mason Burns Well Update Oklahoma (CLICK HERE)

NTRO Completes Stimulation Program: Oklahoma (CLICK HERE)

NTRO Prepares for Rework on Ward-McNeil Well Oklahoma (CLICK HERE)

PWRM) announced today that, in collaboration with Lourdes R. Bosquez, MD, it has unexpectedly discovered new and unprecedented findings regarding clinically important differences in the response of the NuroPro(R) protein biomarkers in the blood of untreated Alzheimer's disease patients compared to patients treated with the widely used anti-dementia drugs Aricept(R) (Donepezil HCl, Pfizer - NYSE: PFE), Exelon(R) (Rivastigmine, Novartis - NYSE: NVS), and Namenda(R) (Memantine HCl, Forest Laboratories - NYSE: FRX). These results relate to the genetically distinct groups of Alzheimer's disease patients, i.e., those individuals who possess the Alzheimer's high-risk gene for Apolipoprotein E4 and those who do not possess the gene.

***NuroPro(R) was originally indicated for diagnostics to determine whether or not a patient had Alzheimer's disease.

***Power3 has filed for patent protection for these findings and will be publishing these seminal results in the near future in one of the world's most prestigious peer-reviewed scientific journals.

***Power3 also plans to demonstrate the clinical application and benefits of its NuroPro(R) diagnostic tests to healthcare providers located throughout the world.

***Power3 believes that this will assist the company greatly in an effort to generate sales of its NuroPro(R) diagnostic tests.

***Power3 is currently working on a joint distribution effort with a number of potential business partners, such as the companies mentioned above, for the sale of its NuroPro(R) diagnostic tests and the development of new drugs.